These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23050745)

  • 21. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
    Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate.
    Davey MP
    Clin J Oncol Nurs; 2002; 6(2):118-20. PubMed ID: 11889677
    [No Abstract]   [Full Text] [Related]  

  • 24. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
    Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
    Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
    Skert C; Patriarca F; Sperotto A; Cerno M; Filì C; Zaja F; Stocchi R; Geromin A; Damiani D; Fanin R
    Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study.
    Ruiz-Argüelles GJ; Gómez-Almaguer D; Morales-Toquero A; Gutiérrez-Aguirre CH; Vela-Ojeda J; García-Ruiz-Esparza MA; Manzano C; Karduss A; Sumoza A; de-Souza C; Miranda E; Giralt S;
    Bone Marrow Transplant; 2005 Dec; 36(12):1043-7. PubMed ID: 16247424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
    Crespo C; Pérez-Simón JA; Rodríguez JM; Sierra J; Brosa M
    Clin Ther; 2012 Aug; 34(8):1774-87. PubMed ID: 22835778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis.
    Benson DM; O'Donnell L; Krugh D; Grady T; Blum W; Williams JD; Kennedy MS; Marcucci G
    Bone Marrow Transplant; 2005 Dec; 36(12):1111-2. PubMed ID: 16247426
    [No Abstract]   [Full Text] [Related]  

  • 30. Ethnic difference may contribute to the efficacy of low-dose imatinib mesylate in systemic sclerosis.
    Tan J; Wei J
    Clin Rheumatol; 2013 Jan; 32(1):149-50. PubMed ID: 23179006
    [No Abstract]   [Full Text] [Related]  

  • 31. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.
    Alvarez-Twose I; González P; Morgado JM; Jara-Acevedo M; Sánchez-Muñoz L; Matito A; Mollejo M; Orfao A; Escribano L
    J Clin Oncol; 2012 Apr; 30(12):e126-9. PubMed ID: 22370312
    [No Abstract]   [Full Text] [Related]  

  • 32. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
    Osorio S; Noblejas AG; Durán A; Steegmann JL
    Am J Hematol; 2007 May; 82(5):394-5. PubMed ID: 17117416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A call for more dermatologic input into chronic graft-vs-host disease clinical trials.
    Cowen EW
    Arch Dermatol; 2009 Mar; 145(3):337-8. PubMed ID: 19289778
    [No Abstract]   [Full Text] [Related]  

  • 34. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
    Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A; Cario-André M; Lepreux S; Rezvani HR; Pasquet JM; Pain C; Schaeverbeke T; Mahon FX; Taïeb A
    Dermatology; 2008; 216(2):109-17. PubMed ID: 18216472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
    Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
    Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Singh T; Casson C
    Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 40. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
    Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.